Kalexo Bio: A New Era in siRNA Therapy for Cardiovascular Health
On September 17, 2025, Mabwell (Shanghai) Bioscience Co., Ltd., a prominent biopharmaceutical entity, and Aditum Bio, a venture firm dedicated to tackling challenging health issues, announced the establishment of Kalexo Bio. This newly formed company aims to spearhead the development of 2MW7141, an innovative dual-target siRNA therapeutic designed for lipid management in patients suffering from dyslipidemia, as well as to help prevent high-risk atherosclerotic cardiovascular disease (ASCVD) events.
The creation of Kalexo Bio underscores a significant collaboration, backed by an exclusive global license agreement between the two firms. This partnership sets the stage for Aditum Bio to back Kalexo Bio financially, as they work collectively to push 2MW7141 into clinical development phases. As part of this initiative, Aditum Bio follows a distinctive incubator model, which enhances the efficiency of drug development, particularly focusing on the translation stage. This model allows for rapid adaptation as they build a dedicated team led by seasoned managers supported by Aditum’s in-house development experts.
In preliminary studies, 2MW7141 has demonstrated remarkable efficacy, showing potent and lasting suppression of target genes while maintaining a low risk of off-target effects. Such findings highlight the therapy’s potential to be a leading option in lipid management, which is crucial as cardiovascular disease continues to be the leading global cause of death. This innovative approach could reshape the standards of care in managing lipid disorders.
Under the terms set forth in their partnership, Mabwell will grant Kalexo Bio exclusive worldwide rights to develop, manufacture, and commercialize 2MW7141. In alignment with this agreement, Mabwell is poised to receive up to $1 billion in upfront and milestone payments, complemented by tiered royalties based on global sales. This financial framework includes $12 million in immediate non-refundable cash payments. Moreover, Mabwell will acquire an equity stake in Kalexo Bio, aligning their interests for mutual success.
The leadership reflects on the transformative impact of Kalexo Bio, with Joe Jimenez, Co-Founder and Managing Director of Aditum Bio commenting, “Cardiovascular disease remains the leading cause of death worldwide, and 2MW7141 represents a novel approach with the potential to change the standard of care in lipid management.” He expressed excitement for the collaboration with Mabwell, emphasizing the intent to accelerate the advancement of this promising siRNA therapy into clinical trials.
Dr. Datao Liu, Founder, Chairman, and CEO of Mabwell, also noted, “The formation of Kalexo Bio marks an important milestone for Mabwell as we expand the global reach of our innovative pipeline. 2MW7141 has demonstrated compelling preclinical results, and we believe that through our partnership with Aditum's experienced team, we can hasten its development and ultimately provide a much-needed therapy to patients at risk of cardiovascular disease worldwide.”
Mabwell Bioscience (688062.SH) is recognized for its focus on delivering innovative biopharmaceuticals that address global health care needs, concentrating particularly on oncology and aging-related diseases. Their mission emphasizes exploring life and enhancing health through innovation, striving to turn ideas into reality. For more insights, visit Mabwell.
Aditum Bio operates as a biotechnology venture firm helicoptering around drug development in sectors denoting high unmet medical needs, effectively licensing promising therapeutic candidates and forming dedicated companies for early trial phases. Interested parties can learn more by visiting Aditum Bio.
Through the establishment of Kalexo Bio, both companies aim to pave a new path towards effective cardiovascular therapies, reflecting their commitment to innovation aimed at improving patient outcomes significantly.
The creation of Kalexo Bio underscores a significant collaboration, backed by an exclusive global license agreement between the two firms. This partnership sets the stage for Aditum Bio to back Kalexo Bio financially, as they work collectively to push 2MW7141 into clinical development phases. As part of this initiative, Aditum Bio follows a distinctive incubator model, which enhances the efficiency of drug development, particularly focusing on the translation stage. This model allows for rapid adaptation as they build a dedicated team led by seasoned managers supported by Aditum’s in-house development experts.
Promising Preclinical Results
In preliminary studies, 2MW7141 has demonstrated remarkable efficacy, showing potent and lasting suppression of target genes while maintaining a low risk of off-target effects. Such findings highlight the therapy’s potential to be a leading option in lipid management, which is crucial as cardiovascular disease continues to be the leading global cause of death. This innovative approach could reshape the standards of care in managing lipid disorders.
Terms of the Agreement
Under the terms set forth in their partnership, Mabwell will grant Kalexo Bio exclusive worldwide rights to develop, manufacture, and commercialize 2MW7141. In alignment with this agreement, Mabwell is poised to receive up to $1 billion in upfront and milestone payments, complemented by tiered royalties based on global sales. This financial framework includes $12 million in immediate non-refundable cash payments. Moreover, Mabwell will acquire an equity stake in Kalexo Bio, aligning their interests for mutual success.
Visionary Leadership Commentary
The leadership reflects on the transformative impact of Kalexo Bio, with Joe Jimenez, Co-Founder and Managing Director of Aditum Bio commenting, “Cardiovascular disease remains the leading cause of death worldwide, and 2MW7141 represents a novel approach with the potential to change the standard of care in lipid management.” He expressed excitement for the collaboration with Mabwell, emphasizing the intent to accelerate the advancement of this promising siRNA therapy into clinical trials.
Dr. Datao Liu, Founder, Chairman, and CEO of Mabwell, also noted, “The formation of Kalexo Bio marks an important milestone for Mabwell as we expand the global reach of our innovative pipeline. 2MW7141 has demonstrated compelling preclinical results, and we believe that through our partnership with Aditum's experienced team, we can hasten its development and ultimately provide a much-needed therapy to patients at risk of cardiovascular disease worldwide.”
About the Companies
Mabwell Bioscience (688062.SH) is recognized for its focus on delivering innovative biopharmaceuticals that address global health care needs, concentrating particularly on oncology and aging-related diseases. Their mission emphasizes exploring life and enhancing health through innovation, striving to turn ideas into reality. For more insights, visit Mabwell.
Aditum Bio operates as a biotechnology venture firm helicoptering around drug development in sectors denoting high unmet medical needs, effectively licensing promising therapeutic candidates and forming dedicated companies for early trial phases. Interested parties can learn more by visiting Aditum Bio.
Through the establishment of Kalexo Bio, both companies aim to pave a new path towards effective cardiovascular therapies, reflecting their commitment to innovation aimed at improving patient outcomes significantly.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.